TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03551782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
Study: NCT04410861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse laser photostimulation
Description: In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse laser photostimulation
Description: In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
Study: NCT03251521

Intervention type: OTHER
Intervention: pain rating during injection with botulinum toxin
Description: The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
Study: NCT00960089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIQUICURE
Description: Topical treatment, 1 time/day, 5 days/week
Study: NCT02563782

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub-retinal transplantation of MA09-hRPE cells
Description: transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus and mycophenolate mofetil
Description: Immunosuppressive Agents

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo tacrolimus and mycophenolate mofetil
Description: placebo

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Sham surgery
Study: NCT03763747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoreflex NC Scoring PTCA catheter
Description: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
Study: NCT00578097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection cycle, intradetrusor injection at baseline (visit 2).
Study: NCT01523938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Pre- (one session) and postoperative (two sessions) Hypnotherapy
Study: NCT02740465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Inventory for Respiratory Disease (AIR)
Description: An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
Study: NCT01960491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Closure of Atrial Septal Defect
Description: Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder
Study: NCT04270422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional physiotherapy
Description: Multidimensional physiotherapy based on biopsychosocial approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy
Description: Usual evidence based physiotherapy
Study: NCT02900014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sampling mesenchymal stem cells
Description: nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
Study: NCT02403596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exacyl®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo of Exacyl®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Exacyl®
Study: NCT01926678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish massage therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Swedish massage therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light touch therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Light touch therapy
Study: NCT01574807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepivacaine + lidocaine followed by lidocaine +lidocaine
Description: 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine + lidocaine followed by mepivacaine + lidocaine
Description: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study: NCT01499771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 Mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 Mg tablets
Study: NCT03174171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 0.75 mg
Description: Everolimus 0.75 mg b.i.d. orally for 14 days.
Study: NCT00705588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Orally, titrated to maximum 20mg od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Orally, titrated to 10 mg bid
Study: NCT00823225

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard therapy
Description: wound debridement, moist wound dressing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU
Study: NCT01617187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Asenapine
Description: Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
Study: NCT04356430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg oral low dose prednisone, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg
Description: 10.8 mg goserelin hypodermic once per 12 weeks
Study: NCT01617187

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Asenapine
Description: Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
Study: NCT03481127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated psychological care
Description: Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: * NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: * NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh tissue from ovary
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tissue from ovary
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery
Study: NCT05123651

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus rhamnosus X253
Description: Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
Study: NCT00988936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]RGD-K5
Description: Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
Study: NCT05123651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus X253
Description: Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus X253
Description: Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
Study: NCT03360136

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-professional CBT-rehabilitation
Description: See Detailed description
Study: NCT02067091

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent implant in a coronary artery
Description: Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent implant in a coronary artery
Description: Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention
Study: NCT02352805

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
Study: NCT02636296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
Study: NCT03586947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 400 UNT Oral Capsule
Description: 50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
Study: NCT03305484

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observation only
Study: NCT05556434

Intervention type: DIAGNOSTIC_TEST
Intervention: radiological evaluation
Description: All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases

Intervention type: DIAGNOSTIC_TEST
Intervention: radiological evaluation
Description: All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases
Study: NCT00984503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
Study: NCT03340714

Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wear ADAMM
Study: NCT04284709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-physical training
Description: combined physical and cognitive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive-physical training
Description: combined physical and cognitive training
Study: NCT01126957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine was given as a 0.5mg / Kg bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given as an bolus to control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
Study: NCT04356430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg
Description: 10.8 mg goserelin hypodermic once per 12 weeks
Study: NCT01126957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol given to both arms to maintain sedation throughout procedure.
Study: NCT02352805

Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
Study: NCT02321137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical closure of left atrial appendage
Description: aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No closure of left atrial appendage
Description: aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
Study: NCT01013896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cystic Fibrosis Education
Description: Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group.
Study: NCT02997384

Intervention type: OTHER
Intervention: Information
Description: information of women about their risk of breast cancer and the screening methods recommended for them

Intervention type: OTHER
Intervention: Information
Description: information of women about their risk of breast cancer and the screening methods recommended for them

Intervention type: OTHER
Intervention: Information
Description: information of women about their risk of breast cancer and the screening methods recommended for them
Study: NCT01929655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
Study: NCT04065087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Investigational drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug